157 related articles for article (PubMed ID: 1697516)
1. Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1990 Oct; 57(1):10-8. PubMed ID: 1697516
[TBL] [Abstract][Full Text] [Related]
2. Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event.
Spitzer RE; Stitzel AE; Tsokos GC
J Pediatr; 1990 May; 116(5):S103-8. PubMed ID: 2329411
[TBL] [Abstract][Full Text] [Related]
3. Autoantibody to the alternative pathway C3/C5 convertase and its anti-idiotypic response. A study in affinity.
Spitzer RE; Stitzel AE; Tsokos GC
J Immunol; 1992 Jan; 148(1):137-41. PubMed ID: 1727863
[TBL] [Abstract][Full Text] [Related]
4. Human polyclonal and monoclonal IgG and IgM complement 3 nephritic factors: evidence for idiotypic commonality.
Tsokos GC; Stitzel AE; Patel AD; Hiramatsu M; Balow JE; Spitzer RE
Clin Immunol Immunopathol; 1989 Oct; 53(1):113-22. PubMed ID: 2475285
[TBL] [Abstract][Full Text] [Related]
5. Human anti-idiotypic antibody responses to autoantibody against the alternative pathway C3 convertase.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1990 Oct; 57(1):19-31. PubMed ID: 2394034
[TBL] [Abstract][Full Text] [Related]
6. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
7. Nucleotide sequence of a human autoantibody to the alternative pathway C3/C5 convertase (C3NeF).
Victor KD; Pascual V; Stitzel AE; Tsokos GC; Capra JD; Spitzer RE
Hybridoma; 1993 Jun; 12(3):231-7. PubMed ID: 8395463
[TBL] [Abstract][Full Text] [Related]
8. [Mechanisms of action and clinical importance of C3-nephritic-factor (author's transl)].
Lanzer G; Pogglitsch H; Tilz GP
Acta Med Austriaca; 1981; 8(1):7-13. PubMed ID: 6908995
[TBL] [Abstract][Full Text] [Related]
9. Further evidence for the antibody nature of C3 nephritic factor (C3NeF).
Daha MR; van Es LA
J Immunol; 1979 Aug; 123(2):755-8. PubMed ID: 379217
[TBL] [Abstract][Full Text] [Related]
10. On the origin of C3 nephritic factor (antibody to the alternative pathway C3 convertase): evidence for the Adam and Eve concept of autoantibody production.
Spitzer RE; Stitzel AE; Tsokos G
Clin Immunol Immunopathol; 1992 Sep; 64(3):177-83. PubMed ID: 1386563
[TBL] [Abstract][Full Text] [Related]
11. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
12. C5 nephritic factors drive the biological phenotype of C3 glomerulopathies.
Marinozzi MC; Chauvet S; Le Quintrec M; Mignotet M; Petitprez F; Legendre C; Cailliez M; Deschenes G; Fischbach M; Karras A; Nobili F; Pietrement C; Dragon-Durey MA; Fakhouri F; Roumenina LT; Fremeaux-Bacchi V
Kidney Int; 2017 Nov; 92(5):1232-1241. PubMed ID: 28712854
[TBL] [Abstract][Full Text] [Related]
13. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
14. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
[TBL] [Abstract][Full Text] [Related]
15. Study of the idiotypic response to autoantibody to the alternative pathway C3/C5 convertase in normal individuals, patients with membranoproliferative glomerulonephritis, and experimental animals.
Spitzer RE; Stitzel AE; Tsokos GC
Clin Immunol Immunopathol; 1992 Mar; 62(3):291-4. PubMed ID: 1541054
[TBL] [Abstract][Full Text] [Related]
16. Different Aspects of Classical Pathway Overactivation in Patients With C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis.
Michels MAHM; van de Kar NCAJ; van Kraaij SAW; Sarlea SA; Gracchi V; Engels FAPT; Dorresteijn EM; van der Deure J; Duineveld C; Wetzels JFM; van den Heuvel LPWJ; Volokhina EB
Front Immunol; 2021; 12():715704. PubMed ID: 34456924
[TBL] [Abstract][Full Text] [Related]
17. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
18. [Progress in the knowledge of complement. II. Nephritic factors].
Leibowitch J; Lesavre P
Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
[No Abstract] [Full Text] [Related]
19. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
20. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
